Back to News
Market Impact: 0.3
Cardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Cardiff Oncology shares fell 5.70% in after-hours trading Tuesday after the clinical-stage biotechnology company announced Leila Alland's appointment as interim chief medical officer. The article provides no further details on the appointment or the share-price decline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
CRDF-0.25
More News
- FedEx beats expectations, raises outlook in first report since calendar adjustment
- Warsh says politics played no role in Fed’s rate decision by group he is ’honored’ to lead
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Tencent’s Cloud Boss Plays Long Game to Patch ‘Leaky’ AI Ship
- Microsoft reveals strong cloud growth amid financial reporting overhaul
- ECB to hold rates as investors focus on French bonds, Lagarde’s future